Publication Name	World Journal of Gastroenterology
Manuscript ID	19487
Country	Türkiye

Received	2015-05-10 15:11
Peer-Review Started	2015-05-12 16:08
To Make the First Decision	2015-09-11 09:22
Return for Revision	2015-09-14 20:26
Revised	2015-10-05 22:13
Second Decision	2015-10-23 16:43
Accepted by Journal Editor-in-Chief	2015-10-25 15:43
Accepted by Executive Editor-in-Chief	2015-11-09 16:59
Articles in Press	2015-11-09 17:00
Publication Fee Transferred
Edit the Manuscript by Language Editor	2015-11-30 17:58
Typeset the Manuscript	2015-12-16 15:54
Publish the Manuscript Online	2016-01-06 16:13

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Frontier
Article Title	Targeted therapies in gastric cancer and future perspectives
Manuscript Source	Invited Manuscript
All Author List	Ozan Yazici, M Ali Nahit Sendur, Nuriye Ozdemir and Sercan Aksoy
Funding Agency and Grant Number
Corresponding Author	Sercan Aksoy, MD, Department of Medical Oncology, Hacettepe University Cancer Institute, Sihhiye, Ankara 06100, Turkey. saksoy07@yahoo.com
Key Words	Targeted therapies; Antibodies; Gastric cancer; Tyrosine kinase; Survival
Core Tip	Trastuzumab was the first molecule shown to prolong both progression-free survival and overall survival in patients with advanced gastric cancer (AGC) when added to first-line chemotherapy in patients with AGC. In 2014, ramucirumab was approved as a single agent or in combination with paclitaxel for the treatment of patients with AGC. Many phase Ⅱ-Ⅲ clinical trials failed to showed activity of different targeted agents in patients with AGC. On the other hand, some molecules have shown promising activity in phase Ⅱ trials and are expected to be in use in the coming years. Pertuzumab and c-Met pathway inhibitors have shown modest activity in a phase Ⅱ trial. The results of two important ongoing phase Ⅲ trials (JACOB and RILOMET-1) may change the recommendations for first-line treatment options in patients with AGC.
Publish Date	2016-01-06 16:13
Citation	Yazici O, Sendur MAN, Ozdemir N, Aksoy S. Targeted therapies in gastric cancer and future perspectives. World J Gastroenterol 2016; 22(2): 471-489
URL	http://www.wjgnet.com/1007-9327/full/v22/i2/471.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i2.471

Full Article (PDF)	WJG-22-471.pdf
Full Article (Word)	WJG-22-471.doc
Manuscript File	19487-Review.doc
Answering Reviewers	19487-Answering reviewers.pdf
Audio Core Tip	19487-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	19487-Conflict-of-interest statement.pdf
Copyright License Agreement	19487-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	19487-Language certificate.pdf
Peer-review Report	19487-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	19487-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	19487-Scientific misconduct check.pdf
Scientific Editor Work List	19487-Scientific editor work list.pdf